Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Bio-Techne (TECH)

Bio-Techne Q1 revenue falls 1% to $286.6 million; adjusted EPS flat at $0.42

Mixed Impact 3 of 5 earnings Written later

Bio-Techne reported results for the first quarter ended September 30, 2025, with net sales down 1% to $286.6 million, GAAP diluted EPS up to $0.24 from $0.21, and adjusted EPS flat at $0.42. The filing also shows the company declared an $0.08 per share dividend and that shareholders elected all nine director nominees and approved executive pay at the annual meeting. For shareholders, the key tension is a smaller revenue base alongside higher GAAP profit.

Key points

  • Net sales fell 1% to $286.6 million; organic revenue also decreased 1%.
  • GAAP diluted EPS was $0.24 versus $0.21; adjusted diluted EPS was $0.42 in both periods.
  • Completed the divestiture of the Exosome Diagnostics business, including the ExoDx Prostate test.
  • Declared a dividend of $0.08 per share, payable November 28, 2025, to holders of record on November 17, 2025.

The filing

CompanyBio-Techne (TECH)
Form8-K, current report
Filed with the SECNov 5, 2025, 6:31 AM ET
Accession number0001104659-25-106631

Items reported: 2.02 Results of Operations5.07 Shareholder Vote Results8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.